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Cancer is a leading cause of death worldwide. The Western dietary pattern is an established risk factor for many
cancers, particularly for colorectal cancer (CRC). The Western diet is typified by the high consumption of red and
processed meats, high fat foods, sugary foods and refined grains, whereas a more prudent diet replaces these foods with
whole grains, fruits and vegetables, many of which are rich in dietary bioactives known to reduce cancer risk.
Agricultural production of many of the foods common to the Western diet is also estimated to have a high envi-
ronmental impact. Thus, diet modification to reduce cancer risk by consumption of more fruits and vegetables would
also be considered a more environmentally sustainable diet.
This review summarizes the impact of dietary bioactives on gastrointestinal health, with a focus on the role of the
gut microbiome and intestinal inflammation in colorectal carcinogenesis. Four dietary bioactives with purported anti-
cancer activities are discussed, including catechins (green tea), anthocyanins (red/blue berries), proanthocyanidins
(cocoa) and isoflavones (soy), with special consideration given to evidence for their interaction with the gut
microbiome. The review concludes with a proposed model for investigating the impact of dietary bioactives for
prevention of colon cancer that incorporates the Western nutritional pattern and considers the role of human gut
microbiota in pre-clinical studies.
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───────────────────────
1. Introduction
In recent years, scientists and policy makers have
become increasingly concerned with the problem of
sustainable production of high quality, nutritious food
(Burchi et al., 2011; O’ Kane, 2012; Institute of
Medicine, 2014). The consensus of these reports is
that, in the 21
st
century, it is not enough to produce
food in sufficient quantity to meet caloric needs of the
world’s population. Food must also meet nutritional
needs, especially with respect to its micronutrient and
bioactive chemical content (i.e., minerals, vitamins and
other food-derived chemicals that affect health).
Recently, the Barilla Center for Food and Nutrition
(BCFN, 2014) finalized its “Double Pyramid” model,
described as a “unique food model created to protect
the wellbeing of people and the environment” (Fig. 1).
The food pyramid depicts recommended dietary
intakes of foods based on a prudent dietary pattern
(modeled after the Mediterranean diet), which is
known to promote health and reduce risk of various
chronic diseases. Alternatively, the environmental
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pyramid represents the estimated environmental im-
pact associated with production of these foods, ranked
from lowest to highest impact. Of critical importance
is the observation that the food items that are re-
commended at the highest intakes for optimal health,
including fruits and vegetables, have the lowest esti-
mated environmental impact.
Many developed nations, including the United
States, are typified by a pattern of food consumption
that conflicts with this double pyramid model. Ameri-
cans tend to consume high amounts of red meats,
processed meats, sweets, high fat foods, refined grains,
high sugar drinks and high fat dairy products ‒ items
that have substantial environmental impact and re-
latively moderate to low nutritional value. Moreover,
the Western dietary pattern is associated with increased
risk of many diseases, including diabetes, obesity,
hypertension, cancer, autoimmune disease, cardio-
vascular disease, and fatty liver disease. Logic
suggests that diet modification represents a safe and
effective strategy to reduce risk of these “Western”
diseases. This strategy has the added societal benefit
in that many of the foods that are believed to reduce
disease risk, particularly fruits and vegetables, are also
those that have low estimated environmental impact.
This review focuses on the impact of dietary bio-
actives on gastrointestinal health, a priority research
topic for the Agricultural Food and Research Initiative
with the U.S. Department of Agriculture and the
principal research area of the Applied Nutrition
Research team at Utah State University. This report
reviews critical statistics on colon cancer risk
worldwide, the impact of diet on cancer, and the role of
the gut microbiome and inflammation in development
of colorectal cancer. We also discuss dietary bio-
actives for cancer prevention, with a focus on selected
bioactives that have been shown to reduce risk of colon
cancer and impact the gut microbiome. Finally, we
highlight two methodological advances that have
allowed us to overcome key challenges facing re-
searchers engaged in pre-clinical research to address
the impact of diet on gut health: 1) a new defined diet
that better emulates typical Western nutrition for
rodent animal models and 2) a new strategy for
humanizing the gut microbiome of rodents. The
review will conclude with a proposed model for
investigating the impact of dietary bioactives for
prevention of colon cancer that incorporates the
Western nutritional pattern and considers the role of
human gut microbiota in pre-clinical studies.
2. Colorectal cancer
Cancer is a leading cause of death worldwide, with
approximately 8. 2 million deaths reported for 2012
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Fig. 1. This diagram represents a simplified version of the “Double Pyramid” (Barilla Center for Food
and Nutrition, 2014), which compares foods ranked in order of recommended intakes for optimal health
to foods ranked in order of estimated environmental impact associated with their production.
(International Agency for Research on Cancer, 2014).
Leading causes of cancer deaths worldwide include
lung, breast, colorectal, prostate, stomach, and liver
cancers (Fig. 2A). Approximately 66% of new cancer
diagnoses are for patients that reside in countries that
are economically developed, whereas 53% of cancer-
related deaths occur in countries that economically
underdeveloped or developing. Moreover, the pattern
of dominant cancers differs according to economic
development status, with breast, prostate, lung,
colorectal and stomach cancers more prevalent in
highly economically developed nations and breast,
cervix, prostate, liver and esophageal cancers more
common in countries with low economic development.
Scientists predict that improvement in economic status
may cause a shift in this disease profile as countries
become more “Westernized,” thus resulting in fewer
cancers caused by chronic infections and leading to a
higher burden of reproductive cancers and diseases
associated with diet and hormonal risk factors.
Colorectal cancer (CRC) is the third most commonly
diagnosed cancer world-wide, with an estimated 1.2
million new cases diagnosed in 2012. A clear dis-
parity in rates of CRC is evident when comparing
developed and developing countries (Fig. 2B,C), as
CRC cases account for about 13% of new diagnoses
(excluding skin cancers) in developed countries (e.g.,
North America) compared to only 7% of new cases
diagnosed in developing countries (e.g., Sub-Saharan
Africa) (American Cancer Society, 2011). In the
U.S., CRC affects primarily those over the age of 50
and has the highest incidence in whites and African
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Fig. 2. Estimated number of cases for the most common cancers worldwide in 2012 (most recent data
available). B) Bars represent the estimated number of colorectal cancer (CRC) cases and the estimated
number of CRC deaths as a percentage of all cancers (excluding non-melanoma skin cancers) for male or
females in developed (dark blue) or developing (light blue) nations. Numbers above the bar represent
the number of cases or deaths. C) World map depicting incidence of colorectal cancers by nation for
both males and females (values shown are the age-standardized rate per 100,000 people). Source data
for panels A and B were obtained from the International Agency for Research on Cancer (2014). Source
data for panel C were obtained from the GLOBOCAN 2012 database (Ferlay et al., 2013).
Americans. The disease is classified as either hered-
itary or sporadic, according to etiology. Hereditary
factors account for about 20% of all cases (Rustgi,
2007), including patients diagnosed with familial
adenomatous polyposis who harbor a mutation in the
adenomatous polyposis coli (APC) gene. Alterna-
tively, sporadic CRC is attributed to environmental and
lifestyle factors, such as diet, physical activity, obesity,
smoking and excess alcohol intake.
A major risk factor for development of CRC is the
presence of chronic inflammation in the colon, which
occurs in patients with inflammatory bowel disease
(IBD). An estimated 1.4 million people suffer from
IBD in the U. S. (Loftus, 2004), including patients
diagnosed with ulcerative colitis (UC) and Crohn’s
disease. Genetic, environmental, lifestyle and immu-
nological factors are believed to contribute to the
development and progression of IBD. The prognosis
for sporadic and IBD-associated CRC is similar, with
survival at five years estimated to be about 50%
(Rhodes and Campbell, 2002). Importantly, re-
searchers have identified clear links between colon
inflammation and increased risk of neoplasia in the
colon mucosa (Dyson and Rutter, 2012; Grivennikov,
2013 and references therein). IBD patients with
prolonged colitis, pan-colitis (involving the whole
large bowel), and severe inflammation are at greatest
risk of developing CRC. Treatment with anti-
inflammatory drugs reduces the risk of developing
IBD-associated CRC, an observation that is consistent
with the involvement of inflammation in colon car-
cinogenesis (Ullman and Itzkowitz, 2011 and re-
ferences therein). Rutter, et al. (2006) made the
critical observation that recovery from colitis in IBD
patients restored their cancer risk level to that of the
general population. Thus, intervention strategies to
enhance recovery from colonic inflammation could
markedly reduce risk of progression to CRC.
Evidence from animal studies has shown that
prolonged chronic inflammation, caused by chemical
injury or by infections that induce colitis, can trigger
DNA damage and colon tumorigenesis (Meira et al.,
2008; Boulard et al., 2012; Mangerich et al., 2012).
Under conditions of inflammation, reactive oxygen
and nitrogen species generated by cells of the innate
immune system also play an important role in trig-
gering genetic and epigenetic changes to colon
epithelial cells, leading to initiation and/or promotion
of tumorigenesis (Hussain et al., 2003). Collectively,
this evidence suggests that inflammation can func-
tionally bypass the initial mutation step, typically to
the APC gene, to initiate colorectal carcinogenesis
under conditions of colitis. Moreover, this evidence
infers that cancer progression could be arrested and
tissue repair achieved if the inflammatory conditions
responsible for the aberrant signaling driving inap-
propriate growth and proliferation of intestinal
epithelial cells are resolved.
3. The Western diet, dietary bioactives
and mechanisms of cancer prevention
Approximately one quarter of all deaths in countries
with a Westernized lifestyle are attributed to cancer
(Boyle and Langman, 2000). The Western dietary
pattern is characterized by high intakes of red and
processed meats, sweets, fried foods and refined
grains, whereas a more balanced diet replaces these
foods with fruits and vegetables, legumes, fish, poultry
and whole grains. In case-controlled and cohort
studies, the typical Western diet is associated with
significantly higher rates of colorectal cancer (CRC)
compared to a balanced diet (Meyerhardt et al., 2007);
environmental factors may contribute approximately
70% of this risk (Doll and Peto, 1981; Wiseman, 2008;
Jemal et al., 2009). The World Health Organization
states that “prevention offers the most cost-effective
long-term strategy for the control of cancer” (World
Health Organization). Regular physical activity, main-
tenance of a healthy body weight and consumption of a
balanced diet may considerably reduce cancer risk.
Diet modification represents a safe and cost-
effective strategy to decrease the incidence of cancer
and delay the onset of the disease. A number of foods
have been identified that may reduce cancer risk with
regular consumption, including certain fruits, vege-
tables and whole grains. These plant-derived foods
contain a variety of components, including vitamins
and minerals, polyunsaturated fatty acids, and various
phytochemicals, that can influence the molecular,
cellular or systemic physiology of the consumer.
Collectively, these essential and non-essential com-
pounds are referred to as dietary bioactives. However,
many individuals consume a diet that is deficient in
these food items and the beneficial micronutrients and
bioactive compounds they provide; the typical Western
diet is emblematic of this problem. For example, con-
sumption of vegetables and micronutrients such as
vitamins B6, B12, D, C and E as well as folate, omega-
Benninghoff et al.: Western Diet, Dietary Bioactives, Gut Microbiota and Colorectal Cancer 37
3 polyunsaturated fatty acids, calcium and selenium
have been linked to decreased risk of colon cancer in
humans (Roynette et al., 2004; Kune and Watson,
2006; Kim and Milner, 2007; Forte et al., 2008;
Pufulete, 2008; Larsson et al., 2010). To date,
hundreds of dietary bioactives have been identified
with proven or suggested beneficial health effects,
including cancer prevention. Many of these com-
pounds are plant-derived chemicals (often referred to
as “botanicals”) in the polyphenol chemical class with
a flavonoid-based structure (Fig. 3). Example source
foods for flavonoids include green tea, various berries
(strawberries, black berries, blueberries, raspberries),
pigmented grains (purple corn), beans (black and
kidney beans), nuts (walnuts, almonds), apples,
artichokes, broccoli, kale, soybean, grapes and grape
juices.
Carcinogenesis is generally considered a multi-step
process, wherein multiple changes to the genetic code
and/or function of cancer critical genes are required to
induce abnormal growth and proliferation of cells,
including processes associated with carcinogen
metabolism, DNA repair, epigenome modification, cell
cycle regulation, apoptosis, and inflammation (see
reviews by Davis, 2007; Sarkar and Li, 2007). Thus,
consumption of dietary bioactives, such as many of
those in the flavonoid group, that function to restore
appropriate cellular signaling by correcting epigenetic
errors, improving DNA repair, inducing cell cycle
arrest or triggering apoptosis in defective cells, may
decrease cancer risk (summarized in Fig. 4). Of
particular interest in the case of colorectal cancer is
inflammation, which occurs as a normal physiological
response to pathogens, irritation or tissue injury.
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Fig. 3. Subclasses of dietary flavonoids, including anthocyanidins, flavonols, flavanols, flavanones and
isoflavones, with example bioactives, some common food sources and a representative chemical struc-
ture for each subclass.
While acute inflammation can be beneficial to the
organism by aiding healing, chronic inflammation is
often detrimental. Chronic inflammation of colon
tissues leads to increased DNA damage, disruption of
DNA repair, aberrant cell proliferation, reduced apo-
ptosis, angiogenesis and invasion of malignant cells to
other tissues. Dietary bioactives that suppress in-
flammation in the colon and/or the secondary effects of
chronic inflammation on colonocytes may be effective
in suppressing colon carcinogenesis.
4. The gut microbiome and its
role in health and disease
Through the concerted action of the National
Institute of Health’s Human Microbiome Project, the
European Commission’s Metagenomics of the Human
Intestinal Tract project and similar consortia across the
world, a wealth of new knowledge has been gained on
the impact of the gut microbiome on health and
disease. Indeed, the number of diseases and conditions
that may be influenced by the composition and
metabolic activities of the gut microbiome is ex-
pansive, with new microbiome-disease connections
reported frequently. Efforts directed towards iden-
tifying specific gut microbiome patterns that are
associated with disease risk and/or pathology severity
are ongoing and are providing new targets for risk
reduction or therapy.
The human gut is host to an ecosystem of more than
100 trillion bacteria, which represent more than 1000
species-level phenotypes across the human population.
Of these, about 160 species are prevalent in any one
individual, and most are classified within two phyla,
Firmicutes and Bacteriodetes. The gut metagenome
Benninghoff et al.: Western Diet, Dietary Bioactives, Gut Microbiota and Colorectal Cancer 39
Fig. 4. Bioactive food compounds can target a variety of cellular processes that are involved in car-
cinogenesis, including carcinogen metabolism, DNA repair, epigenome modification, cell cycle regula-
tion, apoptosis and inflammation. Also shown are selected bioactive compounds that have been shown
to modulate these cellular processes to prevent or suppress cancer development. Selected compounds
are indicated, although this list is not exhaustive.
consists of more than 3 million microbial genes, 150-
fold more than that of the human genome (reviewed in
Arthur and Jobin, 2011). The gut microbiome confers
significant benefit to its host, including metabolism of
indigestible compounds, energy production, defense
against colonization by opportunistic pathogens and
proper development and function of the gut immune
system (reviewed in Round and Mazmanian, 2009).
Changes to an individual’s internal or external envi-
ronment, including personal interactions, lifestyle, age
and pathophysiology, can lead to changes in the gut
microbiome composition and function. Gut micro-
biota modulate various physiological functions related
to cancer development, including inflammation, cell
proliferation, apoptosis and angiogenesis. Thus, it is
likely that the gut microbiome directly affects colon
tumorigenesis. Indeed, a recent report by Zackular, et
al. (2013) showed that conventionalization of germ-
free mice with gut microbiota from animals bearing
colon tumors (generated using a model of inflam-
mation-associated colorectal carcinogenesis) signifi-
cantly increased colon tumorigenesis compared to
mice conventionalized with bacteria from healthy
animals. Importantly, antibiotic treatment caused a
marked decrease in tumor number and size. The
authors concluded that changes in the gut microbiome
associated with inflammation and tumorigenesis
directly contribute to colon tumorigenesis (Zackular et
al., 2013). Recent studies have investigated the
hypothesis that distinct microbiota populations are
associated with CRC (Shen et al., 2010; Sobhani et al.,
2011; Chen et al., 2012; Kostic et al., 2012; Wang et
al., 2012; Ahn et al., 2013; Chen et al., 2013; Geng et
al., 2013). Sobhani et al., (2011) found that micro-
biota from CRC patients clustered distinctly from
matched, cancer free controls. Shen et al., (2010) also
reported that adherent bacteria populations from CRC
patients were significantly different from controls.
Abundance of Dorea and Faecalibacterium species in
CRC patients was higher compared to matched con-
trols, whereas abundance of Bacteroides and
Coprocococcus spp. were lower. Additionally, indi-
vidual bacterial species such as Bacteroides fragilis
(Toprak et al., 2006; Wu et al., 2009), Enterococcus
faecalis (Wang et al., 2008) and Fusobacterium spp.
(McCoy et al., 2013) have all been implicated with
increased CRC risk. From these reports, it is evident
that CRC patients harbor a different gut microbiome
compared to healthy individuals. However, results
from these various studies do not agree with respect to
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Fig. 5. A) Homeostasis between the gut microbiome and the intestinal epithelium exists when a
beneficial bacteria population supports epithelial barrier function and a tolerant immune response. B)
Triggered by genetic or environmental factors, such as diet or stress, dysbiosis can lead to loss of
barrier function, translocation of commensal or pathogenic bacterial, dysregulation of immune response
and inflammation of the intestinal epithelium. C) Excessive, chronic inflammation can promote hyper-
plasia and/or dysplasia of the intestinal epithelium and development of preneoplastic lesions, which may
ultimately progress to form colon tumors.
the composition and structure of the microbial com-
munity associated with CRC ‒ a consensus cancer-
related microbiome has not (yet) been identified.
Maladaptation to a changing environment can lead
to dysbosis, or an imbalance in the structure and/or
function of the gut microbiome. Under homeostatic
conditions, symbiotic or commensal bacteria pre-
dominate, appropriately regulate the immune system
and inhibit growth of pathobionts (Fig. 5). In patients
with chronic inflammation, a shift in the microbiota
population, triggered by a combination of genetic and
environmental factors, can lead to dysregulation of the
immune system, disruption of the epithelial barrier,
increased production of pro-inflammatory and pro-
tumorigenic cytokines, metabolic activation of various
mutagens, loss of protective bacteria species and
accumulation of opportunistic pathobionts (Griven-
nikov, 2013; Kamada et al., 2013). Translocation of
bacteria to the submucosa leads to activation of pattern
recognition receptors, such as toll-like receptors
(TLRs), which in turn activate pro-inflammatory
signaling cascades (e. g., NFκB pathway) leading to
increased expression of pro-inflammatory cytokines
(e.g., IL-1, IL-6, TNF) (Saleh and Trinchieri, 2011).
The gut microbiome can promote carcinogenesis
through multiple mechanisms, such as the promotion
of epithelial inflammation as described above (re-
viewed by Schwabe and Jobin, 2013). The gut
microbiomes of patients with inflammation are distinct
from healthy controls, with consistent observations of
reduced gut microbial biomass, decreased diversity
and richness of the microbial community and altered
relative abundance of members of the dominant phyla,
Firmicutes and Bacteroidetes (Ott et al., 2004; Frank
et al., 2007; Ott et al., 2008). Inflammation of the
intestine in colitis-associated CRC further alters the
microbiome, selecting for overrepresentation of par-
ticular species. Furthermore, colon tumors may
provide a specialized microenvironment that is suitable
for colonization by certain species, such as Fuso-
bacterium spp. (McCoy et al., 2013), which may
function to further promote tumor development. Bac-
terial genotoxins can induce DNA damage in tissues of
the gastrointestinal tract, leading to initiation of
carcinogenesis. Reactive oxygen and nitrogen species
released from inflammatory cells, such as macro-
phages, may also be genotoxic. The gut microbiome
plays an important metabolic role in carcinogenesis, as
well. Carcinogens consumed from the diet or dietary
bioactives may undergo metabolic activation by the gut
microbiome. Importantly, many of the metabolic
products of the gut microbiome can exert both local
and systemic effects.
5. Dietary bioactives and the
gut microbiome.
Knowledge is accumulating regarding the impact of
diet on the gut microbiome and is revealing dietary
approaches to favorably affect the gut microbiome. To
date, a substantial amount of effort has been directed
towards the study of probiotics (live beneficial
bacteria) and prebiotics (fermentable substrates) on the
gut microbiome and the health issue of interest.
Additional attention has been given to the role of
macronutrients in defining both the gut microbiome
and associated diet-derived metabolites (Wu et al.,
2011; Ou et al., 2013; Daniel et al., 2014; David et al.,
2014). In contrast to work done with prebiotics,
probiotics and macronutrients, substantially less at-
tention has been given to the potential for non-
nutritive plant bioactive compound to alter both the gut
microbiome and associated metabolic capabilities.
The potential for dietary flavonoids to favorably alter
the gut microbiome to promote health has been
recognized and recently reviewed (Macdonald and
Wagner, 2012; Tuohy et al., 2012; Etxeberria et al.,
2013; Kemperman et al., 2013). Many flavonoids
occur in plants as a defense mechanism against bac-
terial pathogens and thus have antibacterial properties
(Cushnie and Lamb, 2005). Not surprisingly, studies
conducted in animal models, humans and in vitro
intestinal models demonstrate that the gut microbiota
composition is altered by flavonoid-rich foods and
extracts such as black tea, green tea, coffee, cocoa
flavanols, cruciferous vegetables, blueberries, red wine
polyphenols, or purified catechin and epicatechin (Mai
et al., 2004; Dolara et al., 2005; Tzounis et al., 2008;
Jaquet et al., 2009; Li et al., 2009; Tzounis et al.,
2011; Axling et al., 2012; Hidalgo et al., 2012; Jin et
al., 2012; Massot-Cladera et al., 2012; Queipo-
Ortuno et al., 2012; Sanchez-Patan et al., 2012;
Kemperman et al., 2013; Lacombe et al., 2013). Fig.
6 highlights selected food sources of dietary poly-
phenols and their effects on gut microbiota populations
in humans and rodent models.
Addition of dietary bioactives, especially plant-
derived polyphenols, to the American diet represents a
safe and cost-effective strategy to reduce gut in-
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flammation, promote recovery from injury to the colon
epithelium and decrease the risk of disease pro-
gression. Dietary polyphenols are extensively meta-
bolized by intestinal microbiota. Only 5 to 10% of
ingested polyphenols are absorbed in the small intes-
tine (Clifford, 2004). Thus, the remaining 90 to 95%
are metabolized in the colon by gut microbiota into
numerous different chemical species (Gonthier et al.,
2003; Rechner et al., 2004; Keppler and Humpf, 2005;
Del Rio et al., 2010; Del Rio et al., 2010; Schantz et
al., 2010; Van’t Slot et al., 2010; Andres et al., 2011;
van Duynhoven et al., 2011; Hidalgo et al., 2012;
Moco et al., 2012; Bolca et al., 2013). As opposed to
inactivation through microbial metabolism, pre-
clinical data demonstrate that many of the known
polyphenol metabolites retain anti-inflammation and
anti-cancer bioactivities (Gao et al., 2006; Veeriah et
al., 2007; Larrosa et al., 2009; Forester and
Waterhouse, 2010; Miene et al., 2011; Russell and
Duthie, 2011; Brown et al., 2012; Forester et al.,
2012). Therefore, it is likely that the relationship
between polyphenol intake and colon cancer risk
reduction is more related to end products of microbial
metabolism than the parent polyphenols consumed.
Thus, protection against colon cancer by polyphenols
may be dictated in part by the gut microbiota
population and their metabolic capabilities. Below, we
highlight several classes of dietary bioactives and
present a summary of evidence for involvement of gut
microbiota in their actions, with a focus on plant-
derived polyphenols that have been shown to prevent
or suppress colon carcinogenesis.
5.1 Green tea catechins
Green tea (Camellia sinensis) is the second most
widely consumed beverage in the world and is one of
the richest sources of dietary catechins ((-) -
epicatechin; (-) -epicatechin 3-gallate; (-) -epigal-
locatechin; (-) -epigallocatechin 3-gallate; (+) -
catechin; (+) -gallocatechin) (Singh et al., 2011).
While other foods such as blueberries and cocoa
approach green tea in terms of their content of total
catechins, green tea is unique in its abundance of (-)-
epigallocatechin 3-gallate (EGCG). Routine con-
sumption of green tea has been linked to health
benefits for multiple conditions, including cancer,
obesity, stroke, diabetes, neurodegeneration and stress
(reviewed in Singh et al., 2011). In addition to the
availability of green tea for direct consumption as a
beverage, numerous green tea extracts, purportedly
high in EGCG, are commercially available.
The anticancer effects of green tea and/or its
bioactive catechins are well documented in epidemi-
ological, in vitro cell culture, in vivo animal and human
clinical studies; targets for cancer prevention by green
tea include cancers of the colon, intestine, liver, lung,
ovary, prostate and mammary gland (reviewed in
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Fig. 6. Evidence that select dietary bioactives modulate gut microbiota in humans and in pre-clinical
animal models.
1
(Queipo-Ortuno et al., 2012),
2
(Kemperman et al., 2013),
3
(Dolara et al., 2005),
4
(Lacombe et al., 2013),
5
(Hidalgo et al., 2012),
6
(Jin et al., 2012),
7
(Tzounis et al., 2008),
8
(Tzounis et al.,
2011) and
9
(Massot-Cladera et al., 2012).
Singh et al., 2011). Many cancer critical molecular
targets for tea catechins have been identified, including
targets associated with regulation of the cell cycle,
apoptosis, cell growth, gene transcription, kinase acti-
vity and regulation of the epigenome (Singh et al.,
2011). By virtue of their antioxidant properties, green
tea polyphenols suppress the inflammatory processes
that contribute to carcinogenesis, including suppres-
sion of TNFα expression and NFκB signaling (Yang et
al., 1998; Yang et al., 2001; Mazzon et al., 2005;
Byrav et al., 2011; Kawaguchi et al., 2011), with
evidence of modulation of TLRs (Byun et al., 2012;
Cunha et al., 2013). Consumption of green tea poly-
phenols decreased colonic inflammation, suppressed
TNFα expression and reduced markers of oxidative
stress in rodents with chemically-induced colitis
(Mazzon et al., 2005; Oz et al., 2005; Oz et al., 2013).
Green tea has been studied in different animal
models of gastrointestinal cancer with promising
results. Supplementation of drinking water with
EGCG reduced intestinal tumorigenesis in Apc
min/+
mice, which are genetically predisposed to the
development of small intestinal tumors (Orner et al.,
2003; Ju et al., 2005). The green tea extract poly-
phenon E has been shown to suppress development of
tumors in colons of mice initiated with the carcinogen
azoxymethane (AOM) (Ju et al., 2003; Ju et al., 2007;
Shimizu et al., 2008), and Xiao et al. (2008) showed
that green tea polyphenols suppress development of
aberrant crypt foci in colons of rats initiated with
AOM. Using a mouse model of colon inflammation
where mice are provided the inflammatory agent
dextran sodium sulfate (DSS), Shirakami et al. (2008)
showed that supplementation with polyphenon E or
EGCG suppressed colon tumor development.
Green tea polyphenols are extensively metabolized
by gut microbiota (Schantz et al., 2010; Calani et al.,
2012). Our collaborator recently determined that oral
consumption of green tea polyphenols increases
abundance of Bifidobacterium spp. in mice (Lefevre,
personal communication), similar to observations for
humans consuming green tea (Jin et al., 2012). In a
batch culture in vitro experiment, Tzounis et al. (2008)
showed that (+)-catechin incubation increased growth
of Clostridium coccoides, Bifidobacterium spp., and
Escherichia coli, while attenuating growth of C.
histolyticum.
5.2 Anthocyanins
Anthocyanin-rich foods (certain red, purple and blue
berries and fruits; pigmented grains, nuts and legumes;
red and purple vegetables [but not beets]) and derived
extracts have long been touted for their health
promoting effects pertaining to obesity, diabetes, car-
diovascular disease, inflammation and cognitive func-
tion (Galli et al., 2002; Tsuda, 2012). Dietary sup-
plements containing extracts derived from acai berry,
tart cherry, elderberry, blueberry, bilberry, aronia
(chokeberry) or black currant are widely available for
purchase. The intake of anthocyanins in the U.S. is
estimated to be about 12.5mg/day (Wu et al., 2006);
however, these compounds are poorly absorbed in the
gastrointestinal tract.
Anthocyanidins (the aglycone form of anthocya-
nins), such as cyanidin and delphinidin, modulate a
variety of cell signaling pathways involved in
inflammation, carcinogenesis and angiogenesis, in-
cluding suppression of expression and/or signaling
through COX-1 and -2, iNOS, Akt, ERK1/2, TNFα,
NFκB, IL-6 and IL-8 (see Domitrovic, 2011; Chen et
al., 2014). Oral consumption of black raspberry
powder (Rubus occidentalis), which has high cyanidin
content, provided significant protection against
chemically-induced colitis via suppression of pro-
inflammatory pathways (lower TNFα and IL-1β
expression, reduced activity of NFκB and COX-2 in
the colon) (Montrose et al., 2011). Moreover, dietary
supplementation with anthocyanin-rich extracts from
tart cherries, pomegranate or purple sweet potato
reduced tumorigenesis in the gastrointestinal tract of
rodents (Kang et al., 2003; Bobe et al., 2006; Banerjee
et al., 2013; Lim et al., 2013). Anthocyanins are
reported to have anti-microbial activity (Cisowska et
al., 2011; Miladinovic et al., 2014), and the gut
microbiome of mice fed anthocyanins from purple corn
is very distinct from that fed a standard diet (Lefevre et
al., 2011). In an in vitro fecal batch culture system,
Hidalgo et al. (2012) reported that a mixture of an-
thocyanins from grape peel (containing primarily
malvidin-, delphinidin- and petunidin-3-glucosides)
enhanced growth of Bifidobacterium spp. and Lacto-
bacillus spp. Finally, evidence from in vitro, animal
and human volunteer studies shows that anthocyanins
are metabolized extensively by the gut microbiome
(reviewed in Williamson and Clifford, 2010). Inter-
estingly, Salyer et al. (2012) reported that consumption
of anthocyanin-rich blackberries conditioned the gut
microbiome in mice to more effectively metabolize
cyanidin-3-glucoside in vitro.
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5.3 Proanthocyanidins
Proanthocyanidins are condensed flavan-3-ols and
are abundant in cocoa, chocolate, grape seeds and skin,
cinnamon, nuts and certain berries (blueberries, choke
berries, cranberries). These sources differ with respect
to the degree of flavan-3-ol polymerization and type of
linkage. Health benefits ascribed to consumption of
proanthocyanidin-rich foods and supplements include
improvements in insulin sensitivity and inflammation,
reduced risk for cancer, cardiovascular disease and
urinary tract infections (Ouedraogo et al., 2011; Gu
and Lambert, 2013; Krueger et al., 2013; Yang and
Xiao, 2013).
Cocoa powder contains high amounts of flavonoids,
including the monomers (‒)-epicatechin and catechin
and various catechin-based polymers, termed pro-
cyanidins (reviewed in Ramiro-Puig and Castell,
2009). Some cocoa-derived products can deliver as
much or more polyphenolic antioxidants as other fruit
or tea products (Lee et al., 2003; Vinson et al., 2006).
Proanthocyanidins from cocoa (as high as 517mg/40 g
serving of dark chocolate) have been shown to have
antioxidant and anti-inflammatory properties in vitro
(Vinson et al., 2006; Rodriguez-Ramiro et al., 2011;
Rodriguez-Ramiro et al., 2012). Most in vivo studies
on the effects of cocoa polyphenols have employed
cocoa powder or a commercial cocoa or chocolate
product enriched in polyphenols. For example, dietary
supplementation with 0.24% cocoa polyphenols via
cocoa powder provided significant protection against
colonic inflammation in rats and suppressed activity of
NFκB and expression of pro-inflammatory enzymes
COX2 and iNOS in the colon (Rodriguez-Ramiro et
al., 2013). Consumption of a cocoa-rich diet also
reduced development of pre-neoplastic lesions in rats
initiated with AOM (Rodriguez-Ramiro et al., 2011;
Hong et al., 2013). In healthy human volunteers,
consumption of a cocoa drink with high polyphenol
content for 4 wk significantly increased Bifidobac-
terium spp. as well as Lactobacillus and Enterococcus
spp., while abundance of C. histolyticum was reduced
(Martin et al., 2012). Cocoa consumption in rats was
also shown to modulate the gut microbiome, leading to
a decrease in abundance of members of the Bac-
teroides, Clostridium and Staphylococcus genera, but
no apparent changes in abundance of Lactobacilllus or
Bifidobacterium (Massot-Cladera et al., 2012). Final-
ly, a number of reports have shown that cocoa
proanthocyanidins are metabolized by the gut micro-
biome (Tzounis et al., 2008; Fogliano et al., 2011).
5.4 Soy isoflavones
Much attention has been given to the apparent link
between diet and the lower rate of many cancers in
Asian populations compared with US residents, with
particular focus on the contribution of soy and soy-
based bioactive food components, such as the
isoflavone compounds genistein and daidzein (re-
viewed in Wu et al., 2009; Andres et al., 2011).
Evidence from human and animal studies suggests that
consumption of soy-based foods and/or soy iso-
flavones is associated with reduced risk of risk of
several malignancies, including cancers of the
mammary gland, ovary, bladder, colon, liver, pancreas,
lung, head and neck as well as lymphoma and
leukemia (reviewed in Andres et al., 2011). Also,
others have shown that dietary soy inhibits de-
velopment of pre-neoplastic lesions in the colon
(Zhang et al., 2013). Alternatively, there is continued
concern that isoflavone consumption is positively
associated with risk of endometrial cancer or
abnormalities reproductive development based on
evidence from animal studies (Santell et al., 1997;
Newbold et al., 2001; Rachon et al., 2007).
Genistein and daidzein are well known ligands for
the estrogen receptor (ER), and much of their anti-
cancer activities are attributed to modulation of ER-
dependent cell signaling. Alternatively, genistein has
also been shown to modulate the epigenome via
inhibition of the activity of DNA methyltransferase,
the enzyme responsible for establishing the meth-
ylation code and directing expression of many key
tumor suppressor genes (reviewed in Zhang and Chen,
2011; Rietjens et al., 2013). While much of the cancer
prevention research with soy isoflavones has focused
on genistein, there is increased interest in the health
benefits (or reduced risks) of complex soy mixtures in
the form of extracts (Gallo et al., 2006) or soy flour
(Allred et al., 2004; Allred et al., 2005).
One of the best characterized examples of a dietary
bioactive interacting with the gut microbiome to
influence human health is the microbial conversion of
soy isoflavones to equol, a non-steroidal estrogenic
compound. Many of the cancer protective properties
of soy are thought to be derived through the conversion
of soy isoflavones to equol, which has been shown to
be inversely related to prostate and breast cancer
incidence in Asian populations (Lampe, 2010). Pro-
duction of equol from the soy isoflavone daidzein
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requires a gut microbiome with that specific metabolic
capacity, yet only about one-third of the population has
a resident gut microbiome that can generate equol
(Yuan et al., 2007). Thus, an individual’s microbiome
likely influences the potential chemo-preventative
properties of dietary soy. Importantly, routine soy
consumption appears to impact the composition of the
gut microbiome by positively selecting for bacteria that
are equol-producers. In countries that traditionally
consume soy, such as Japan, China, and Korea, it is
estimated that 50 to 60% of the population has a
microbiome capable of producing equol (Setchell and
Clerici, 2010). In contrast, only 25 to 30% of West-
erners can produce equol after consuming isoflavones.
Therefore, the potential beneficial effects of soy in
prevention of cancer are nuanced and dependent and
on an individual’s routine diet and gut microbial
population.
6. Current challenges and new strategies
6. 1 Modeling the typical western diet in pre-
clinical animal studies
The typical Western diet is characterized by in-
expensive, highly processed foods that are rich in
calories, but low in many essential micronutrients. As
most micronutrients are acquired through the diet,
consumption of energy-dense, nutrient-poor foods may
result in micronutrient intakes below Recommended
Daily Allowances (RDAs). RDAs are formulated to
prevent deficiency diseases in the U.S. population.
However, new evidence suggests that chronic low
intakes of micronutrients can negatively affect meta-
bolic processes without triggering the physical mani-
festation of acute deficiency (reviewed in Ames,
2005). Although these low nutrient intakes do not
trigger symptoms of acute deficiency, other adverse
health effects from chronic low dietary exposure are
possible, including increased risk or acceleration of
chronic, degenerative diseases such as cancer, car-
diovascular disease and diabetes. While some studies
have investigated the health effects of chronic low
consumption of single micronutrients (Ames, 2005),
information regarding the impact of chronic low intake
of multiple micronutrients on disease outcome is
lacking, especially in the context of a typical Western
diet.
In most studies investigating the contribution of
functional foods, bioactive food components and
micronutrients for disease prevention (especially can-
cer), researchers routinely employ standard diets that
are generally balanced with respect to macro- and
micronutrient levels to optimize rodent health, such as
the AIN diets formulated by the American Institute of
Nutrition (Reeves et al., 1993). In mechanistic studies
with model organisms, nonessential nutrients or whole
food extracts are often added to these AIN diets to
investigate cancer protective effects, or conversely,
levels of individual macronutrients or micronutrients
are altered to determine their role in carcinogenesis.
While this strategy has led to significant findings, our
contention is that a rodent diet more representative of
the diet consumed by the majority of Americans is
necessary to appropriately evaluate colon cancer risk
and to develop specific and effective prevention
strategies. Some scientists have sought to address this
issue by employing “cafeteria” style diets (animals are
free to select from a variety of tasty processed foods) in
an attempt to emulate typical Western dietary patterns
for rodent disease models. However, the cafeteria diet
has limited value as an experimental model because it
is poorly defined with respect to micronutrient com-
position and unlikely to provide for robust experi-
mental replication (Moore, 1987; Rothwell and Stock,
1988). Commercial Western diets have also been
developed for the study of obesity, namely the DIO
diets, which typically contain 45% or 60% of energy as
fat and differ from the AIN diets primarily in their high
lard and sucrose content (Gajda, 2008). Although
these high fat diets effectively induce obesity in
rodents (Jawien et al., 2004), they are extreme in their
sugar and fat compositions when compared to a typical
Western dietary pattern and do not differ substantially
from AIN diets in micronutrient content (Gajda, 2008).
Importantly, none of these approaches for modeling
typical Western nutrition has appropriately considered
the contribution of suboptimal micronutrient intake in
their disease models.
To address this resource gap, our group developed
the new total Western diet (TWD) for rodents with
energy and nutrient profiles that emulate a typical
Western diet using available U.S. survey data
(NHANES) (Hintze et al., 2012). Briefly, the amount
of each macro- and micronutrient in the AIN93G basal
diet, a diet routinely used in cancer studies today, was
adjusted to match 50
th
percentile intakes for Americans
as reported in NHANES survey data. These mass
amounts were then adjusted for caloric intake. The
TWD has fewer calories from protein and carbohydrate
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sources and twice that from fat as compared to the
AIN-93 diet. The new diet contains more saturated
and monounsaturated fats, less polyunsaturated fat,
more complex carbohydrates and twice the level of
simple sugars. TWD includes less calcium, copper,
folate, thiamine and vitamins B6, B12, D and E, but
much more sodium. Overall, the TWD is not nec-
essarily extreme in the level of any given nutrient, but
rather reflects the overall dietary pattern of the U.S.
This newly devised diet that better represents typical
U.S. nutrition is highly useful for studies employing
animal models of human cancer.
6.2. Modeling the human gut microbiome in pre-
clinical studies
The field of gut microbiology and associated human
health outcomes has advanced greatly through the use
of “humanized” mouse models (Gootenberg and
Turnbaugh, 2011; Turnbaugh et al., 2009; Goodman
et al., 2011). Traditionally, these models require
seeding germ-free mice with microbiota from human
donors, thus providing a useful system to study the
interactions between human microbiota and chronic
disease in situations where human subjects are not
appropriate. However, maintenance of germ-free
mouse colonies is expensive and requires substantial
institutional investment in infrastructure and spe-
cialized personnel. Moreover, germ-free mice are not
readily available for the most common and/or most
important strains used in health research, including
many inbred and genetic mouse models. Thus, to
efficiently model the human microbiome in mice, we
developed a humanized mouse model using broad-
spectrum antibiotics and human fecal transfer (Hintze
et al., 2014).
Briefly, the human microbiota fecal transfer method
involves the following steps (Fig. 7A): 1) depleting
resident animal intestinal microbiota by gavaging the
animal twice daily for 17 days with broad spectrum
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Fig. 7. A) Recommended protocol for establishing a humanized gut microbiome in rodents is shown,
including periods of antifungal and antibiotic administration (light and dark green lines) and the timing of
oral gavage with donor fecal material (circled T). See Hintze et al. (2014) for complete protocol details. B)
Chart depicts results following weekly fecal transfer from two human donors to recipient mice using the
protocol outlined in panel A. Values shown are the fraction of bacteria sequence mass in recipient mice
that originated exclusively from the donor (human), that were shared by the donor and the recipient
mouse (both), that were present only in the original mouse microbiome (mouse) or that were not
detected in the original human or mouse microbiomes (neither).
antibiotics (ampicillin, vancomycin, neomycin and
metronidazole) and an antifungal (amphotericin B); 2)
introducing human microbiota, derived from frozen
fecal samples, by oral gavage weekly; and 3) main-
taining the animals in microisolator cages supplied
with HEPA filtered air. After 17 days, mice in the
fecal transfer treatments were gavaged with fecal
material reconstituted in sterile saline from one of two
human donors (donor 1 or 2). Mice were gavaged
weekly with fecal material from their respective donors
until for up to 12 weeks. To assess the effectiveness of
this transfer method, bacteria populations of the ceca
were characterized by traditional 16S rRNA pyro-
sequencing. The resulting data were then compared by
weighted Unifrac analysis to distinguish differences in
the microbiome between treatments. We determined
that the microbiome from control mice (no antibiotics),
antibiotic-only treated mice and mice receiving either
human donor 1 or 2 inoculant were distinct from each
other. In mice inoculated with human donor sample,
approximately 57 to 68% of the donor sequence mass
was recovered in the respective recipient mice (Fig.
7B) (Hintze et al., 2014). Additionally, an analysis of
microbial-derived metabolites revealed that the gut
microbiomes of mice inoculated with material from
donors 1 and 2 were also distinct (Hintze et al., 2014).
These data show that our fecal transfer protocol caused
substantial changes to the cecal metabolome and that
our method is sufficiently robust such that phenotypic
differences between mice humanized with microbiota
from different human donors are readily apparent.
Thus, we expect that humanized mice generated from
our protocol can be used for investigations into the
contribution of human intestinal bacteria on the
etiology of disorders linked to gut microbiota such as
colon cancer, inflammatory bowel disease, obesity,
diabetes and autism (Kinross et al., 2008; Rowland,
2009; Iebba et al., 2011; Marteau and Chaput, 2011;
Musso et al., 2011; Cucchiara et al., 2012; Kootte et
al., 2012; Lawrance, 2012; Tehrani et al., 2012).
Although our approach to humanize the gut
microbiome of laboratory animals is technologically
straightforward, this method has the potential to
dramatically impact this field of science. Other in-
vestigators who have successfully humanized mouse
intestinal microbiota relied on the use of germ-free
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Fig. 8. Proposed model for investigating the impact of dietary bioactives for prevention of colon
cancer by incorporating different nutritional patterns (prudent diet versus Western type diet) and
human gut microbiota (via new humanized gut microbiome model) as part of the study design.
mice as recipients and subsequent maintenance of the
animals in a dedicated, germ-free vivarium
(Turnbaugh et al., 2009); however, this approach has
substantial (and potentially insurmountable) limita-
tions. Most important of these is the availability of
germ-free mice in only a few mouse strains. The vast
majority of well-characterized inbred mouse strains
and genetically modified mice, all of which are es-
sential models for the study of human disease, are not
commercially available as germ-free. This represents
a significant limitation to the vast majority of research
groups who wish to examine the impact of human
microbiota populations in animal models of human
disease, but lack the means to derive germ-free animals
from the appropriate strain of interest. Also of note,
this new approach can be extended to other highly used
animal model species (rats, hamsters, etc.). To put it
simply, mice of any strain or genetic model can have
their intestinal microbiota humanized on demand as
needed by the investigator following this protocol for
human microbiota transfer to rodents.
7. Conclusions
While abundant evidence from pre-clinical studies
supports the strategy of diet modification to reduce
cancer risk, there still exist many knowledge gaps on
the role of dietary bioactives for modification of the
gut microbiome to influence disease development.
The role of gut bacteria in maintaining health and the
impact of dysbiosis of the microbiota ecosystem in
triggering or exacerbating disease is widely recognized
(e.g., Round and Mazmanian, 2009; Guinane and
Cotter, 2013; Schwabe and Jobin, 2013; Festi et al.,
2014; Giannelli et al., 2014; Sanz et al., 2014; Schippa
and Conte, 2014; Tojo et al., 2014; Lei et al., 2015;
McLean et al., 2015). Yet, the impact of the gut
microbiome on the efficacy of many dietary bioactives
for preventing cancer has been relatively overlooked.
Moreover, given the observations that basal diet can
markedly influence the composition of the gut micro-
biome and that different gut microbiota populations
confer different metabolic activities towards dietary
bioactives, it is critically important to consider the
impact of both basal diet and the gut microbiome in
animal studies investigating dietary bioactives as
chemopreventive agents. Thus, we propose an inte-
grated, more translational methodological approach for
such studies (Fig. 8) that incorporates the Western type
diet (macro- and micronutrient composition) as part of
the experiment design and utilizes a humanized gut
microbiome to address the role of gut bacteria in health
maintenance and/or disease development. The de-
velopment of the new total Western diet and a straight-
forward protocol for human microbiota fecal transfer
support this new experimental model.
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